Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study - Li, Shanshan; Wu, Xiaojie; Li, Nanyang; Cao, Guoying; Wang, Jingjing; Chen, Yuancheng; Li, Size; He, Jinjie; Wu, Jufang; Yang, Haijing; Lin, Ke; Qiu, Chao; et al. (Frontiers in pharmacology, 2023)
Keywords: COVID-19; HFB30132A; monoclonal antibody; neutralizing antibody; Pharmacology; safety; SARS-CoV-2; COVID-19; SARS-CoV-2; safety; pharmacokinetics; neutralizing antibody; monoclonal antibody; HFB30132A; immunogenicity